Next Generation Capsule Endoscopy Video Data Acquisition and Visualization Platfo

描述（由申请人提供）：胃肠道恶性肿瘤是世界上最常见的癌症原因。在全球每年1080万癌症患者中，约330万人患有胃肠道恶性肿瘤。除了预防之外，迫切需要有效、低成本和舒适的早期诊断技术来改善这一状况。传统的内窥镜或放射性成像方法给患者带来明显的不适，昂贵或缺乏灵敏度。目前的胶囊内窥镜（CE）成像技术是一项重大的技术突破。然而，它仍然存在前视视场效果不佳、图像质量差、诊断观察时间长等缺点。Altrum科技公司与梅奥诊所合作，在SBIR项目中提出开发一种新型光学成像胶囊和视频数据可视化/分析硬件/软件系统，称为GISentinelTM，用于下一代CE技术。基于我们正在申请专利的360度成像光学系统，GISentinel具有独特的图像打开和强大的全景配准技术，将具有以下临床影响和意义：3/4 GI成像的跨跃式技术：GISentinel胶囊作为可吞咽的药丸，可提供即时的360度图像，不受胃肠道组织壁的机械影响，因此不会给患者带来不适-不再有传统内窥镜插入管的镇静或疼痛。3/4不遗漏胃肠道疾病区域：GISentinel胶囊提供完整的360度胃肠道周围，不会遗漏任何区域。3/4准确快速诊断：GISentinel SW通过更有效的图像配准，有望帮助GI医生/护士快速（低至0.5小时）准确诊断异常。3/4低成本胶囊系统，更好的大众接受和有效的疾病预防：由于其简单的结构和光学设计，如果超过1000个，GISentinel胶囊的制造成本约为55美元。3/4可扩展和可扩展的技术：为GISentinel开发的专有全方位技术可以很容易地应用于现有的诊断仪器（内窥镜、结肠镜、胃镜等），为患者提供类似的好处。千禧研究集团预测，胶囊内窥镜市场仅在美国就将从2004年的4000万美元增长到2008年的5亿多美元。根据给定成像有限公司的数据，全球有近100万患者使用他们的PillCam胶囊进行了胶囊内窥镜检查。胶囊内窥镜是一个快速增长的数十亿美元的市场。拟议的GISentinel系统和技术的商业化潜力是巨大的。

DESCRIPTION (provided by applicant): Gastrointestinal (GI) malignancies are the most common cause of cancer in the world. Of the 10.8 million people in the world each year who develop cancer, approximately 3.3 million have GI malignancies. Aside from prevention, effective, low cost, and comfortable early diagnosis technologies are urgently needed to improve this situation. Traditional endoscopic or radioactive imaging methods present significant discomfort to the patients, is costly, or lack sensitivity. Current capsule endoscopy (CE) imaging technique represents great technological breakthrough. However, it still has drawbacks such as ineffective forward looking FOV and poor image quality, and requests long diagnosis viewing time. Altrum Technologies, Inc. in collaboration with Mayo Clinic proposes in this SBIR project to develop a novel optical imaging capsule and video data visualization/analysis hardware/software system called GISentinelTM for the next generation CE technology. Built on our patent pending 360 degree imaging optics, with unique image unwrapping and robust panoramic registration techniques, GISentinel will have the following clinic impact and significance: 3/4 A leapfrog technology for GI imaging: Used as a swallowable pill, GISentinel capsule offers instant 360o images mechanically free for GI tract tissue wall, thus causing no discomfort to patients - no more sedation or pain from the tube insertion of traditional endoscopes. 3/4 No missing GI disorder areas: GISentinel capsule offers a complete 360o surrounding of the GI tract, no area will be missed. 3/4 Accurate and rapid diagnosis: Through more effective image registration, GISentinel SW is expected to help GI doctors/nurses to rapidly (down to 0.5 hours) and accurately diagnose abnormalities. 3/4 A low cost capsule system for better mass acceptance and effective disease prevention: Due to its simple structural and optical design, GISentinel capsule can be manufactured at a cost of around $55 if over a quantity of 1000. 3/4 Expandable and scalable technology: The proprietary omni-directional technology developed for GISentinel can be easily applied to existing diagnosis instruments (endoscopes, colonscope, gastroscope, etc) to provide similar benefits to the patients The Millennium Research Group predicated the capsule endoscopy market is to generate more than $500 million in 2008 in the United States alone - up from just $40 million in 2004. According to Given Imaging Ltd., close to 1 million patients worldwide have gone through capsule endoscopy procedures using their PillCam capsules. Capsule endoscopy is a rapidly-growing multi-billion dollar market. The commercialization potential of the proposed GISentinel system and technology is significant. PUBLIC HEALTH RELEVANCE: The GISentinelTM system and technology developed under this SBIR project will provide great benefit to GI patients by providing a low cost and non-invasive method for early GI tract disease diagnosis and prevention. GISentinel provides an innovative panoramic imaging and mosaic technique leading to much shorter diagnosis time with more accurate results. With the extended capability over current pill cameras, GISentinel is expected to have a reasonably large market share of this multi-billion dollar industry. In addition, GISentinel technology will also benefit non-medical fields such as commercial perimeter surveillance, and water and gas pipe inspection.